In the past week, KROS stock has gone up by 10.07%, with a monthly gain of 3.90% and a quarterly surge of 17.66%. The volatility ratio for the week is 4.87%, and the volatility levels for the last 30 days are 5.63% for Keros Therapeutics Inc The simple moving average for the past 20 days is 3.98% for KROS’s stock, with a 12.24% simple moving average for the past 200 days.
Is It Worth Investing in Keros Therapeutics Inc (NASDAQ: KROS) Right Now?
Additionally, the 36-month beta value for KROS is 1.21. There are mixed opinions on the stock, with 11 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for KROS is 30.20M and currently, short sellers hold a 7.36% ratio of that float. The average trading volume of KROS on December 04, 2024 was 381.45K shares.
KROS) stock’s latest price update
Keros Therapeutics Inc (NASDAQ: KROS)’s stock price has gone rise by 9.78 in comparison to its previous close of 56.73, however, the company has experienced a 10.07% increase in its stock price over the last five trading days. benzinga.com reported 2024-12-03 that On Tuesday, Takeda Pharmaceutical Company Limited TAK entered into an exclusive licensing agreement with Keros Therapeutics, Inc. KROS to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau.
KROS Trading at 4.48% from the 50-Day Moving Average
After a stumble in the market that brought KROS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.68% of loss for the given period.
Volatility was left at 5.63%, however, over the last 30 days, the volatility rate increased by 4.87%, as shares surge +3.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.19% upper at present.
During the last 5 trading sessions, KROS rose by +10.07%, which changed the moving average for the period of 200-days by +4.69% in comparison to the 20-day moving average, which settled at $59.90. In addition, Keros Therapeutics Inc saw 56.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KROS starting from GORDON CARL L, who sale 250,000 shares at the price of $44.01 back on Aug 13 ’24. After this action, GORDON CARL L now owns 119,522 shares of Keros Therapeutics Inc, valued at $11,002,500 using the latest closing price.
ORBIMED ADVISORS LLC, the Director of Keros Therapeutics Inc, sale 250,000 shares at $44.01 during a trade that took place back on Aug 13 ’24, which means that ORBIMED ADVISORS LLC is holding 119,522 shares at $11,002,500 based on the most recent closing price.
Stock Fundamentals for KROS
Current profitability levels for the company are sitting at:
- -313.42 for the present operating margin
- -0.27 for the gross margin
The net margin for Keros Therapeutics Inc stands at -278.91. The total capital return value is set at -0.37. Equity return is now at value -43.82, with -40.10 for asset returns.
Currently, EBITDA for the company is -152.18 million with net debt to EBITDA at 2.6. When we switch over and look at the enterprise to sales, we see a ratio of 3089.71. The receivables turnover for the company is 0.34for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.03.
Conclusion
In conclusion, Keros Therapeutics Inc (KROS) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
